Form 4: Mona Ashiya, Director at Disc Medicine, Reports Indirect Sale of Shares

Director Mona Ashiya reports indirect sales of Disc Medicine (IRON) common stock through affiliated entities.

Summary

• Mona Ashiya, a director of Disc Medicine, Inc. (IRON), filed a Form 4 disclosing transactions involving the sale of common stock.
• The sales were executed on March 24, 2025, at a price of $54.11 per share.
• The transactions involved the indirect disposition of shares held by OrbiMed Private Investments VI, LP (OPI VI), OrbiMed Private Investments VIII, LP (OPI VIII), and OrbiMed Genesis Master Fund, L.P. (Genesis).
• After the reported transactions, the number of shares beneficially owned indirectly by OPI VI is 482,308, by OPI VIII is 746,171 and by Genesis is 186,541.
• Mona Ashiya disclaims beneficial ownership of the securities except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard disclosure of stock sales. The sales themselves could be interpreted in various ways, but the filing itself is simply a procedural requirement.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders may react to the insider selling activity, potentially impacting the stock price.

Key Dates

Keywords

Form 4, Beneficial Ownership, Disc Medicine, IRON, Mona Ashiya, OrbiMed, Share Sale, Director